Joint Oncology Unit - LICR Melbourne Centre for Clinical Sciences

MELBOURNE CENTRE FOR CLINICAL SCIENCES

Research > Joint Oncology Unit

Joint Austin Ludwig Oncology Unit

The Medical Oncology was established with the philosophy that new cancer treatments are essential if we are to make progress in delivering the best care to people with cancer. The aim of the unit is simple: to provide the very best care to cancer patients and to conduct high quality clinical cancer research in an integrated environment. The Joint Unit is where research and patient care meet.

A unique partnership between Austin Health and the Ludwig Institute For Cancer Research has been forged to achieve this. Austin is responsible for providing the very latest medical care and the Institute is responsible for providing clinical research opportunities.

At any one time the Oncology Unit conducts a substantial number of clinical trials with much of this effort being directed towards Institute studies, particularly in the field of cancer immunotherapy. Many of these are performed under the auspices of the Cancer Vaccine Collaborative (CVC). The CVC is an international collaborative effort involving scientists and physicians from around the world who have joined together under the banner of the Cancer Research Institute (CRI) and Ludwig Institute.

Publications

1. Azad, A., Chionh, F., and Cebon, J., Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. Asia Pacific Journal of Oncology, (5): p. 76-86 2009.

2. Davis, I.D., Brady, B., Kefford, R.F., Millward, M., Cebon, J., Skrumsager, B.K., Mouritzen, U., Hansen, L.T., Skak, K., Lundsgaard, D., Frederiksen, K.S., Kristjansen, P.E., and Mcarthur, G., Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial. Clin Cancer Res, 15(6): p. 2123-9 2009.

3. Davis, I.D. and Desai, J., Clinical use of therapies targeting tumor vasculature and stroma. Curr Cancer Drug Targets, 8(6): p. 498-508 2008.

4. Cebon, J., Gedye, C., John, T., and Davis, I.D., Immunotherapy of advanced or metastatic melanoma. Clinical Advances in Hematology & Oncology, 5(12): p. 994-1006 2007.

5. Nicholaou, T., Wong, R., and Davis, I.D., Tumour lysis syndrome in a patient with renal cell carcinoma treated with sunitinib malate. The Lancet, 369: p. 1923-1924 2007.

6. Cebon, J., Findlay, M., Hargreaves, C., Stockler, M., Thompson, P., Boyer, M., Roberts, S., Poon, A., Scott, A.M., Kalff, V., Garas, G., Dowling, A., Crawford, D., Ring, J., Basser, R., Strickland, A., Macdonald, G., Green, M., Nowak, A., Dickman, B., Dhillon, H., and Gebski, V., Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer, 95(7): p. 853-61 2006.

Click Here For More

Research Links

	Overview
	Tumour Targeting Laboratory
	Cancer Vaccine Laboratory
	T Cell Laboratory
	Uro-Oncology Laboratory
	Oncogenic Transcription Laboratory
	Joint Austin Ludwig Oncology Unit
	Centre for PET
	Key Technologies

Joint Oncology Unit Staff

Director Joint Oncology Unit

Prof Jonathan Cebon

Staff Directory

Jonathan Cebon - Unit Director
Ian Davis - Medical Oncologist
Niall Tebbutt - Medical Oncologist
Hui Gan - Medical Oncologist

Patient Resources

	Victorian Cancer Agency
	Cancer Council of Victoria
	Cancer Trials Australia
	Clinical Trials (USA)
	Cancer Net (USA)
	Cancer.gov (USA)
	CancerBACUP (UK)
	Joint Oncology Unit